New York - Paul Hastings, a leading global law firm, announced today that the firm represented Deerfield Management on the creation of Bluefield Innovations, a collaborative partnership with Johns Hopkins University and aimed at the development of early stage therapeutics. Bluefield Innovations brings together a leading investment firm with a prominent academic research institution with the goal of bringing therapeutics from the lab to the clinic and ultimately to market.
Bluefield will provide up to $65 million in initial funding over five years to support the commercialization of early stage therapeutic research at Johns Hopkins, with additional funding available to advance research showing strong commercial potential. Research developed within Bluefield will either be licensed to third parties or spun out into new companies.
Deerfield Management launches Bluefield Innovations, a therapeutics partnership with Johns Hopkins University.
The Paul Hastings team was led by partner Samuel Waxman, and also included partner Andrew Short and associates Michael Vargas and Brooke Schachner.
Earlier this year, Paul Hastings represented Deerfield in the formation of a research partnership with The Broad Institute of MIT and Harvard, and in 2016, Paul Hastings advised Deerfield Management in connection with the formation of Bridge Medicines, a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine.
At Paul Hastings, our purpose is clear—to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.